Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Perrigo Company F4Q09 (Qtr End 06/27/09) Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions The first question comes from the line of David Buck – Buckingham Research. David Buck – Buckingham Research First on Consumer Health can you talk about the level that you assumed in your guidance of price degradation if any and specifically...
- Earnings calls 2009-08-18
Additional Resources
- OMEPRAZOLE--FDA.
- OMEPRAZOLE--FDA has approved Astra Merck Inc.'s 10-day, triple therapy regimen combining Prilosec omeprazole with antibiotics ... OMEPRAZOLE--FDA has approved Astra Merck Inc.'s 10-day, triple therapy regimen combining Prilosec omeprazole with antibiotics Biaxin clarithromycin and amoxicillin for the treatment of Helicobacter pylori infection in patients with...
- Research articles 1998-07-20
- Santarus Begins Pivotal PK/PD Clinical Trial for Rapinex — Omeprazole — Capsule 20mg
- SAN DIEGO -- Santarus, Inc. (Nasdaq:SNTS) today announced that the company has begun a pivotal pharmacokinetic/pharmacodynamic (PK/PD) clinical trial evaluating RapinexR Capsules, one of its immediate-release omeprazole products. This trial will compare a 20-mg dose of its Rapinex omeprazole Capsules to a 20-mg dose of delayed-release omeprazole capsules in approximately...
- Research articles 2004-07-15
- MYLAN Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(gets FDA approval for omeprazole delay-release capsules)(Brief Article)
- MYLAN Laboratories Inc. has received final Food and Drug Administration FDA approval for its abbreviated new drug application for omeprazole ... MYLAN Laboratories Inc. has received final Food and Drug Administration FDA approval for its abbreviated new drug application for omeprazole delayed-release capsules,...
- Research articles 2003-06-09
- OMEPRAZOLE.
- Astra AB has signed an agreement with Schering-Plough Corporation to reacquire from Schering-Plough's subsidiary, Essex Chemie, the rights to market Losec (omeprazole, antiulcer) and Perfudal/ Prevex (felodipine, and-hypertension) in ... Astra AB has signed an agreement with Schering-Plough Corporation to reacquire from Schering-Plough's...
- Research articles 1998-12-21
- P&G targets OTC omeprazole. (News).(Proctor and Gamble)(Brief Article)
- PROCTER & GAMBLE Company (P&G) and AstraZeneca PLC AZ are gearing up for a nonprescription over-the-counter OTC version of AZ's Prilosec omeprazole. Upon approval by the Food and Drug Administration FDA, the companies expect US sale PROCTER & GAMBLE Company (P&G) and AstraZeneca PLC...
- Research articles 2002-06-24
- AstraZeneca to Appeal German Court Decision Against Omeprazole Patents.(Brief Article)
- ASTRAZENECA WILL appeal a ruling by the German Federal Patent Court that nullified the formulation patent for omeprazole in Germany. The patent covering the formulation was scheduled to expire in 2007. It has been subject to nullity actions by gene ASTRAZENECA WILL appeal a...
- Research articles 2000-03-27
- Omeprazole. (Pharma in Brief).(Mylan Pharmaceuticals launches delayed release capsules)(Brief Article)
- OMEPRAZOLE Mylan Laboratories Inc., through its wholly owned subsidiary Mylan Pharmaceuticals Inc., has launched 10 mg and 20 mg omeprazole delayed release capsules. The drug is the generic version of AstraZeneca PLC's Prilosec.
- Research articles 2003-08-11
- Santarus Announces Positive Results from Pivotal PK/PD Clinical Trials for ZEGERID — Omeprazole — Capsules 20mg and 40mg
- SAN DIEGO -- Company Initiates Pivotal PK/PD Clinical Trial for ZEGERID Omeprazole Chewable Tablets 40mg
- Research articles 2004-11-09
- Santarus Announces Positive Results from Pivotal PK/PD Clinical Trials for ZEGERID — Omeprazole — Chewable Tablets 20 mg and 40 mg
- SAN DIEGO -- Santarus, Inc. (Nasdaq:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that the primary objectives were met in its pivotal pharmacokinetic/pharmacodynamic (PK/PD) clinical trials evaluating ZEGERIDTM omeprazole Chewable Tablets 20 mg and 40 mg. Following final analysis of the clinical trial...
- Research articles 2005-02-09
- Impax Laboratories reported that Teva Pharmaceutical Industries launched Impax's omeprazole delayed-release 20 mg capsules, the generic version of AstraZeneca's Prilosec, marketed by Procter & Gamble for the treatment of duodenal/gastric ulcers and ga
- Impax Laboratories reported that Teva Pharmaceutical Industries launched Impax's omeprazole delayed-release 20 mg capsules, the generic version of AstraZeneca's Prilosec, marketed by Procter & Gamble for the treatment of duodenal/gastric ulcers and gastroesophageal reflux disease. According to NDCHealth, U.S. sales of Prilosec 20 mg and its generic equivalents reached $1.2...
- Research articles 2004-09-27
- Andrx, AstraZeneca in Generics Battle.(over drug patent issues surrounding Prilosec)(Brief Article)
- VYING TO BE first in the generics market for AstraZeneca's AZ $6 billion drug Prilosec omeprazole, Andrx says final marketing approval of its omeprazole abbreviated new drug application ANDA may be delayed as Food & Drug Administration ad VYING TO BE first in the...
- Research articles 2001-10-15
- Astrazeneca PLC (AZ). (Markets: Life Sciences).(Brief Article)
- ASTRAZENECA PLC AZ suffered blows in its battle to fend off generic competition for Prilosec omeprazole, a $6 billion ulcer drug, in a district court in New York. The court ruled patent '342 covering the use of omeprazole as an antimicrobial ag ASTRAZENECA PLC...
- Research articles 2002-04-29
- FDA panel thumbs down on OTC Prilosec
- An FDA advisory committee voted on October 20 not to recommend an over-thecounter version of AstraZeneca's Prilosec omeprazole magnesium. Omeprazole magnesium OM 20 mg is a new formulation of omeprazole developed for OTC use. During the meeting, the FDA reviewers told the committee that it was unclear whether the overall...
- Research articles 2000-12-01
- AstraZeneca Introduces Next Generation Prilosec.(Brief Article)
- Company tries to offset the expiration of its patent. WITH PATENT EXPIRY for AstraZeneca's Prilosec omeprazole looming, the company has developed a racemically pure version of the drug that it expects to launch next year. The upgraded versio Company...
- Research articles 2000-09-18
- AstraZeneca wins Prilosec lawsuit ruling as Andrx shares sink. (Life Sciences).
- ASTRAZENECA PLC AZ has won a high-stakes patent-infringement lawsuit against generic manufacturers of its blockbuster ulcer drug Prilosec omeprazole, reducing the number of near-term generic competitors from four to one. ASTRAZENECA PLC AZ has won a high-stakes patent-infringement lawsuit against generic...
- Research articles 2002-10-21
- Generic onslaught could permanently alter PPI market.(Pharmaceuticals)
- THE UNPRECEDENTED success of AstraZeneca's Prilosec omeprazole generated a maelstrom of interest in the market for proton pump inhibitors PPIs. New drugs, including the follow-on to Prilosec, Nexium esomeprazole, and Altana's Protonix (pantop THE UNPRECEDENTED success of AstraZeneca's Prilosec omeprazole generated a maelstrom...
- Research articles 2003-08-18
- AstraZeneca's Crestor gets European approval. (Markets: Life Sciences).
- ASTRAZENECA PLC has received its first European approval for Crestor rosuvastatin, a drug the company will rely on heavily to offset the impact of generic Prilosec omeprazole. ASTRAZENECA PLC has received its first European approval for Crestor rosuvastatin, a drug the company...
- Research articles 2002-11-18
- Active pharmaceutical ingredient watch. (Markets: Life Sciences/Specialties).(AstraZeneca PLC had solid results for 2002)(Brief Article)
- ASTRAZENECA PLC posted solid results for 2002, despite the launch of generic Prilosec omeprazole in December. Underlying earnings per share EPS grew 7 percent to $1.84, ahead of Goldman Sachs estimates by 6 cents, on sales up 9 percent (23 perc ASTRAZENECA PLC posted...
- Research articles 2003-02-10
- AstraZeneca in Generics Battle.(against Cheminor Drugs Ltd., Reddy-Cheminor Inc. over Prilosec)(Brief Article)
- ASTRAZENECA HAS filed a complaint in a US district court over its blockbuster drug Prilosec omeprazole against Cheminor Drugs Ltd., and Reddy-Cheminor Inc. alleging patent infringement. AstraZeneca also says it will refrain from listing three new ASTRAZENECA HAS filed a complaint in a US...
- Research articles 2001-09-03
- << Previous
- page 1 of 1
- Next >>
